NEWS RELEASE RYTVEL Antenatal suppression of ... RELEASE RYTVELA totally prevents fetal organ injury...
Transcript of NEWS RELEASE RYTVEL Antenatal suppression of ... RELEASE RYTVELA totally prevents fetal organ injury...
NEWSRELEASE
RYTVELAtotallypreventsfetalorganinjuryininflammatory-inducedPTBinmiceRytvela–newtreatmentparadigmforpretermbirth(PTB)andensuedconsequences
Montreal,Canada,February16,2017–RYTVELBiotechispleasedtoannouncethatthearticle:Antenatal suppressionof interleukin-1protectsagainst inflammation-induced fetal injuryandimproves neonatal and developmental outcomes in mice was published in the Journal ofImmunology.Seebelowforinformationaboutthearticle.
MathieuNadeau-Vallée,Peck-YinChin, LydiaBelarbi,Marie-ÈveBrien,SheetalPundir,MartinH.Berryer,AlexandraBeaudry-Richard, Ankush Madaan, David J. Sharkey, Alexis Lupien-Meilleur, Xin Hou, Christiane Quiniou, InesBoufaied, Jean-Sebastien Joyal, William D. Lubell, David M. Olson, Sarah A. Robertson, Sylvie Girard and SylvainChemtob.
In a previous article, published in September 2015 in the same journal, the authors havedemonstrated that Rytvela reduces utero-placental inflammation and is efficacious to restorenormaltermforbirth,andsignificantlyreducesnewborndeathyieldingnormalgrowthtrajectory.
Thesedatacamefromthreedifferentblinded,separateandindependentstudiesofPTBinduceseitherbyIL-1,LPSorLTA.
The new publication uses the same design to the previous one but concentrates on neonataldeathandoutcome,withfocusonbrain,lungsandgut.TheauthorsshowthatRytvelacompletelyprotectsfetal/newbornorgansfromtheinflammatoryinuteroinsult.Itshouldbehighlightedthatbrainfunctionassessedbyvisual-evokedpotentialwastotallypreservedinanimalstreatedwithRytvela(versusmarkedlyaffectedcontrols).
Rytvelaisanewefficientfirstinclasstreatmentofthecauseandensuingseriousconsequencesofpretermbirth.
“Weareagainveryencouragedwiththesenewresultswhichfocusonfetaloutcome,themainproblemofPTB,”saidSylvainChemtob,MD,PhD,co-founderofRytvelBiotechandresearcheratCHUSainte-Justine.“Pretermbirth(PTB) istheprimarycauseofmortalityofnewbornandlongterm health disability mainly respiratory distress syndrome, bronchopulmonary dysplasia,necrotizing enterocolitis, retinopathy of prematurity and brain hemorrhage, and there are noeffectivetreatmenttodaythataddressescriticallyimportantutero-placentalinflammationtotheplacentaandfetus.Rytvelaoffersnotonlytoprolonggestationbyallowingincreasedmaturationof the fetus, but also reduces neonatal mortality and improves fetal/neonatal outcome, mostimportantlyregardingneuro-development.Thisisafirst”.The article “Antenatal suppression of interleukin-1 protects against inflammation-induced fetalinjury and improves neonatal and developmental outcomes in mice” is available athttps://rytvel.com/news-publications-and-credentials/,belowthenewsreleases.
AboutRYTVELBiotechandRytvelaRYTVEL Biotech will be the first company exploring a new paradigm therapy to developRytvela, aneffectivedrugtoendpretermbirthtothebenefitofwomenandnewborns.Rytvela(alinear7aminoacid
peptide)isthefirstsmalldrugcandidateselectivetothemajorpro-inflammatoryinterleukin-1receptor.Pre-clinicalstudieshavebeencorroboratedbythreeindependentacademiclaboratories(UofMontreal,U of Alberta in Canada, andU of Adelaide, Australia). These blinded studies performed separately andindependently demonstrate that Rytvela suppresses utero-placental inflammation, significantlyreduces/suppressespretermbirth(PTB),newborndeathandpreventsmajororgandisruptionincludingofbrain,yieldingnormalgrowthtrajectory.RytvelawasinventedbyDrSylvainChemtobandhisteamattheCHUSainte-JustineResearchCenterinMontreal,Canada.www.rytvel.comAbouttheCHUSainte-JustineResearchCenterCHUSainte-JustineResearchCenterisaleadingmother-childresearchinstitutionaffiliatedwithUniversitédeMontréal.Itbringstogethermorethan200researchinvestigators,includingover90clinician-scientists,as well as 385 graduate and postgraduate students focused on finding innovative prevention means,fasterandlessinvasivetreatments,aswellaspersonalizedapproachestomedicine.TheCenterispartofCHU Sainte-Justine, which is the largestmother-child center in Canada and second pediatric center inNorthAmerica.www.research.chusj.orgAboutPTB(Pretermbirth)PTB isdefinedasbirthoccurringbefore37weeksofgestationandbefore32weeks forearlypre-term.PTBoccursin~10%ofbirths(~550,000inNorthAmerica).EarlyPTBin2to3%ofbirth.ThemajorcauseofPTB isutero-placental inflammation.The consequencesarenewborndeath (more than1millionperyearworldwide), severe life-longhealthhandicaps especially tobrain, lungs and cardiovascular system.The current treatments, namely tocolytic agents have no or very little efficacy, and none of themaddressestheutero-placentalinflammation.ThecostsrelatedtoPTBintheUSAwerereportedin2017tobe$40billion/year.AbouttheJournalofimmunologyThe Journalof Immunology (The JI) publishesnovel,peer-reviewed findings inall areasofexperimentalimmunology, including innateandadaptive immunity, inflammation,hostdefense, clinical immunology,autoimmunityandmore.TheJIispublishedbyTheAmericanAssociationofImmunologists(AAI)andhasanimpactfactorof5.22.
MediaContact:DanielGranger,L.LL.,MBA,APR,FSCRP,IAST.+1514840-7990M.+1514232-1556daniel.granger@acjcommunication.comACJCommunicationScientific,FinancingandBDContacts:JeanPaulCastaigneMD,[email protected]+1514518-5500
SylvainChemtobMD,[email protected]+1514585-4604